Vinflunine: A new microtubule inhibitor agent

Clinical Cancer Research

Volumn 14, Issue 6, 2008, Pages 1625-1632

  Bennouna, Jaafar ^a   Delord, Jean Pierre ^b   Campone, Mario ^a   Nguyen, Laurent ^c  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPOTHILONE DERIVATIVE; GEMCITABINE; MITOMYCIN; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; VINBLASTINE; VINCRISTINE; VINFLUNINE;

ABDOMINAL PAIN; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG ACTIVITY; DRUG BINDING; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HEADACHE; HUMAN; INFUSION SITE REACTION; INJECTION SITE REACTION; JAW PAIN; LEUKOPENIA; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MICROTUBULE; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PARESTHESIA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; STOMATITIS; SURVIVAL TIME; THORAX PAIN; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; UROGENITAL TRACT TUMOR; VOMITING;

ANIMALS; BREAST NEOPLASMS; CARCINOMA; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; LUNG NEOPLASMS; MODELS, BIOLOGICAL; NEOPLASMS; TREATMENT OUTCOME; TUBULIN MODULATORS; UROLOGIC NEOPLASMS; UROTHELIUM; VINBLASTINE;

EID: 41549152173     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-2219     Document Type: Review

References (47)

1. Jacquesy JC, Fahy J. Cancer: superacid generation of new antitumor agents. Biomedical chemistry: applying chemical principles to the understanding and treatment of disease. Paul F. Torrence (ed). John Wiley & Sons, Inc. 2000.
2. Kruczynski A, Hill BT. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Crit Rev Oncol Hematol 2001;40:159-73.
3. Ngan VK, Bellman K, Panda D, et al. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res 2000;60:5045-51.
4. Ngan VK, Bellman K, Hill BT, et al. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol 2001;60:225-32.
5. Kruczynski A, Barret JM, Etievant C, et al. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated vinca alkaloid. Biochem Phamacol 1998;55:635-48.
6. Pourroy B, Carré M, Honoré S, et al. Low concentrations of vinflunine induce apoptosis in human SK-N-SH neuroblastoma cells through a postmitotic G1 arrest and a mitochondrial pathway. Mol Pharmacol 2004;66:580-91.
7. Simoens C, Vermorken JB, Korst AEC, et al. Cell cycle effects of vinflunine, themost promising Vinca alkaloid andits interactionwith radiation, in vitro. Cancer Chemother Pharmacol 2006;58:210-8.
8. Kruczynski A, Etievant C, Perrin D, et al. Characterization of cell death induced by vinflunine, the most recent Vinca alkaloid in clinical development. Br J Cancer 2002;86:143-50.
9. Jean-Decoster C, Brichese L, Barret JM, et al. Vinflunine, a new Vinca alkaloid: cytotoxicity, cellular accumulation and action on the interphasic and mitotic microtubule cytoskeleton of PtK2 cells. Anticancer Drugs 1999;10:537-43.
10. Okouneva T, Hill BT, Wilson L, Jordan MA. The effects of vinflunine, vinorelbine and vinblastine on centromere dynamics. Mol Cancer Ther 2003;2:427-36.
11. Lobert S, Ingram JW, Hill B, et al. A comparison of thermodynamic parameters for vinorelbine and vinflunine induced tubulin self-association by sedimentation velocity. Mol Pharmacol 1998;53:908-15.
12. Pasquier E, Honore S, Pourrou B, et al. Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 2005;65:2433-40.
13. Kruczynski A, Poli M, Dossi R, et al. Antiangiogenic, vascular-disrupting and antimetastatic activities of vinflunine, the latest Vinca alkaloid in clinical development. Eur J Cancer 2006;42:2821-32.
14. Holwell SE, Hill BT, Bibby MC. Anti-vascular effects of vinflunine in the Mac 15a transplantable adenocarcinoma model. Br J Cancer 2001;84:290-5.
15. Kruczynski A, Colpaert F, Tarayre JP, et al. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated vinca alkaloid. Cancer Chemother Pharmacol 1998;41:437-47.
16. Hill B, Fiebig H, Waud WR, et al. Superior in vivo experimental antitumour activity vinflunine relative to vinorelbine in a panel of human tumour xenografts. Eur J Cancer 1999;35:512-20.
17. Bonfil RD, Russo DM, Binda MM, et al. Higher antitumor activity of vinflunine than vinorelbine against an orthopicmurinemodel of transitional cell carcinoma of the bladder. Urol Oncol 2002;7:159-66.
18. Etievant C, Barret JM, Kruczynski A, et al. Vinflunine (20′,20′-difluoro-3′,4′-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro. Invest New Drugs 1998;16:3-17.
19. Esteve MA, Carre M, Bourgarel-Pey, et al. Bcl-2 down-regulation and tubulin subtype composition are involved in resistance of ovarian cancer cells to vinflunine. Mol Cancer Ther 2006;5:2824-33.
20. Etievant C, Kruczynski A, Barret JM, et al. Markedly diminished drug resistance-inducing properties of vinflunine (2-¶, 2-¶-difluoro- 3¶, 4¶ dihydrovinorelbine) relative to vinorelbine, identified in murine and human tumour cells in vivo and in vitro. Cancer Chemother Pharmacol 2001;48:62-70.
21. Barret JM, Etievant C, Hill BT. In vitro synergistic effects of vinflunine, a novel fluorinated Vinca alkaloid, in combination with other anticancer drugs. Cancer Chemother Pharmacol 2000;45:471-6.
22. Shnyder SD, Cooper PA, Gysenlinck N, et al. Vinflunine potentiates the activity of cisplatin but not 5-fluorouracil in a transportable murine adenocarcinoma model. Anticancer Res 2003;23:4815-21.
23. Bennouna J, Fumoleau P, Armand JP, et al. Phase I and pharmacokinetic study of the new Vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumors. Ann Oncol 2003;14:630-7.
24. Vermorken JB, Stupp R, Nguyen L, et al. Phase I study of i.v. vinflunine given on a weekly schedule in previously untreated patients with advanced solid tumours. Proc Am Soc Clin Oncol 2003;22:221 (Abs. 887).
25. Johnson P, Geldart T, Fumoleau P, et al. Phase I study of vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks. Invest Drugs 2006;24:223-31.
26. Focan CNJ, VanHeugen JC, Kreutz F, et al. Vinflunine metabolismand dispositionincancerpatients. Proc Am Soc Clin Oncol 2002;21:124a (abstract 495).
27. Paule B, Saliba F, Gil-Delgado M-A, et al. Phase I and pharmacokinetic (PK) dose-adjusted study of IV vinflunine (VFL) in cancer patients with liver dysfunction (LD) - pharmacokinetic results. J Clin Oncol 2007;25:2523.
28. Culine S, Theodore C, De Santis M, et al. A Phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 2006;94:1395-14.
29. Goerge C, Petrylak D, Srinivas S, et al. Phase II study of single-agent vinflunine in platinum-refractory transitional cell carcinoma of the urothelium (TCCU). Eur J Cancer 2007;5:309 (abstract 4534).
30. Campone M, Cortes-Funes H, Vorobiof D, et al. Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane based chemotherapy. Br J Cancer 2006;95:1161-6.
31. Fumoleau P, Cortes-Funes H, Chan S, et al. Phase II study of i.v. vinflunine (VFL) as third-line treatment of metastatic breast carcinoma after failure of anthracycline-/taxane-based chemotherapy. Breast Cancer Res Treat 2006;100:S279 (abstract 6070).
32. Bennouna J, Breton JL, Tourani JM, et al. Vinflunine: an active chemotherapy for treatment of advanced non-small cell lung cancer previously treated with a platinum-based regimen. Results of a phase II study. Br J Cancer 2006;94:1383-8.
33. Krzakowski M, Douillard JY, Jassem J, et al. Phase III study of vinflinine versus docetaxel in patients with advanced non-small cell lung cancer previously treated with a platinum containing regimen. Proc Am Soc Clin Oncol 2007;25 (abstract 7511).
34. Talbot DC, Margery J, Dabouis G, et al. Phase II study of vinflunine in malignant pleural mesothelioma. J Clin Oncol 2007;25:4751-6.
35. Olver IN, Byrne MJ, Vorobiof D, et al. Phase II study of vinflunine in patients with chemotherapy naïve metastatic malignant melanoma. Eur J Cancer 2007;43:1829-32.
36. Goldstein D, Ackland SP, Bell DR. Phase II study of vinflunine in patients metastatic renal cell carcinoma. Invest New Drugs 2006;24:429-34.
37. Bennouna J, Campone M, Delord JP, et al. Vinflunine: a novel antitubulin agent in solid malignancies. Expert Opin Investig Drugs 2005;14:1259-67.
38. Ramlau R, Souquet PJ, Sun X, et al. Results of a phase I/II and pharmacokinetic study of vinflunine (VFL) in combinationwith cisplatin (CDDP) for primary treatment of advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004;23:640 (abstract 7110).
39. Lemarié E, Bennouna J, Grossi F, et al. Vinflunine (VFL) in combination with gemcitabine (GEM) for treatment of advanced non-small cell lung cancer (NSCLC) in chemonaive patients (pts): Preliminary results of a phase I and pharmacokinetic study. Proc Am Soc Clin Oncol 2005;23 (abstract 7266).
40. Tourani JM, Pinel MC, Planchard D, et al. Phase I and pharmacokinetic study of Vinflunine (VFL) in combination with carboplatin (CBDCA) for treatment of advanced non-small cell lung cancer (NSCLC) in chemonaive patients (pts): Final results. Proc Am Soc Clin Oncol 2005;23 (abstract 7271).
41. Campone M, Fumoleau P, Roché H, et al. A dose-finding and pharmacokinetic study of I.V. vinflunine (VFL) in combination with capecitabine (CAPE) as second line treatment of metastatic breast cancer (MBC). Breast Cancer Res Treat 2006;100:S279 (abstract 6069).
42. Paridaens R, Wildiers F, Dalenc O, et al. Vinflunine in combinationwith trastuzumab for treatment of HER2-positive metastatic breast cancer. Proc Am Soc Clin Oncol 2007;25 (abstract 1058).
43. Choy H, Park C, Yao M. Current status and future prospect for satraplatin: an oral platinum analogue. Clin Cancer Res 2008;14:1618-23.
44. Lee JJ, Swain SM. The epothilones: translating from the laboratory to the clinic. Clin Cancer Res 2008;14:1643-9.
45. Teicher BA. Newer cytotoxic agents: attacking cancer broadly. Clin Cancer Res 2008;14:1650-7.
46. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008;14:1634-42.
47. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN, Jr., Gandara DR. Aurora kinases as anticancer drug targets. Clin Cancer Res 2008;14:1624-33.